Skip to main content

Table 2 Local dose constraints for PTV, bladder and rectum and the number of plans meeting these constraints

From: Radiotherapy-induced toxicity in prostate cancer patients with hip prostheses

Local dose constraint Number of plans meeting constraint
Control group Prostheses group (IMRT clinical plan) Prostheses group (VMAT replan)
PTV V95% > 98% 50 (100%) 16 (94%) 17 (100%)
PTV V105% < 2% 50 (100%) 17 (100%) 17 (100%)
Rectum V42Gy < 60% 49 (98%) 10 (59%) 16 (94%)
Rectum V50Gy < 50% 49 (98%) 14 (82%) 16 (94%)
Rectum V54Gy < 30% 49 (98%) 13 (76%) 16 (94%)
Rectum V58Gy < 15% 46 (92%) 16 (94%) 16 (94%)
Bladder V42Gy < 55% 43 (86%) 10 (59%) 14 (82%)
Bladder V50Gy < 40% 40 (80%) 9 (53%) 14 (82%)
Bladder V62Gy < 5% 41 (82%) 11 (65%) 14 (82%)